15754-60-6

Basic information

• Product Name: 1-tert-Butyl-1H-pyrazole
• Synonyms: 1-tert-Butyl-1H-pyrazole;1-(1,1-Dimethylethyl)-1H-pyrazole;N-tert-Butylpyrazole;1-(tert-Butyl)
• CAS NO: 15754-60-6
• Molecular Formula: C₇H₁₂N₂
• Molecular Weight: 124.18358
• Mol File: 15754-60-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 167.7±9.0 °C(Predicted)
• Appearance: /
• Density: 0.92±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.31±0.10(Predicted)
• CAS DataBase Reference: 1-tert-Butyl-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-tert-Butyl-1H-pyrazole(15754-60-6)
• EPA Substance Registry System: 1-tert-Butyl-1H-pyrazole(15754-60-6)

Safety Data

• Hazardous Substances Data: 15754-60-6(Hazardous Substances Data)

Usage

General Description

1-tert-Butyl-1H-pyrazole is a chemical compound with the molecular formula C7H12N2. It is classified as a pyrazole, which is a five-membered aromatic ring with two nitrogen atoms at opposite positions. The "1-tert-butyl" group refers to the presence of a tert-butyl (or 1,1-dimethylethyl) substituent on the pyrazole ring. 1-tert-Butyl-1H-pyrazole has been studied for its potential use in pharmaceuticals and as a building block for organic synthesis. It may possess various biological activities, and its unique molecular structure makes it of interest for further investigation in drug development and other applications. Additionally, its tert-butyl group provides steric hindrance, which can enhance the compound's stability and reactivity in chemical reactions.

Upstream product

• 102-52-3 malonaldehydebis(dimethylacetal) 
• 7400-27-3 tertbutylhydrazine hydrochloride 
• 288-13-1 NH-pyrazole 
• 507-20-0 tertiary butyl chloride 

Downstream Products

• 288-13-1 NH-pyrazole 
• 115-11-7 isobutene 
• 97421-12-0 1-tert-butyl-4-nitropyrazole 
• 70951-85-8 4-bromo-1-(1,1-dimethylethyl)-1H-pyrazole 
• 1256359-15-5 1-(1,1-dimethylethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1354705-41-1 1-(tert-butyl)-4-iodo-1H-pyrazole 

Relevant articles and documents

PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted heteroaryls of formula 1 or of formula 1' wherein A is either N or CH, wherein R2 is selected from the group consisting of -C1-3-alkyl, -C1-3-haloalkyl, F, Br, CI, wherein Y is selected from -O- or -CH2-, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.

7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS

The present invention relates to a compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.

KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.